12/08/2025
Novidade na Oftalmologia que esta chegando, algo que promete mudar o mercado da presbiopia, influenciar o uso de óculos, lentes intraoculares e a nossa independência visual.
The U.S. Food and Drug Administration (FDA) has approved VIZZ, developed by LENZ Therapeutics, to treat presbyopia—an age-related condition that blurs near vision, usually in people over 45.
VIZZ is the first FDA-approved aceclidine-based eye drop for this condition, offering a non-surgical alternative to reading glasses.
It works by slightly tightening the iris to create a “pinhole effect,” sharpening near vision without affecting distance vision.
In clinical trials, VIZZ improved near vision within 30 minutes, with effects lasting up to 10 hours. Side effects were mostly mild and temporary, such as slight eye irritation, dim vision, or headache.
LENZ plans to release free samples in October 2025 and make VIZZ widely available by late 2025.
